 |
|
|
| |
Biomarkers, Imaging, & Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor Beta Agonist,
for 52 Weeks
|
| |
| |
EASL 2022 June 22-26 London
Stephen A. Harrison,1 Kris V. Kowdley,2 Rebecca A. Taub,3 Naim Alkhouri,4 Guy W. Neff5
1University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX, USA; 2Liver Institute Northwest, Seattle, WA, USA;
3Madrigal Pharmaceuticals, Conshohocken, PA, USA; 4Arizona Liver Health, Tucson, AZ, USA; 5Covenant Metabolic Specialists,
Sarasota, FL, USA
|
| |
|
|
|
|
|
